University of Oxford’s autonomous driving software developer Oxbotica has secured $47m in a series B round featuring IP Group as well as several corporates.

Jubilant Foodworks is providing $12.9m for the barbeque restaurant operator at a valuation of about $115m.

The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Utec has made its largest initial commitment to date by backing Keio-founded Metcela, a developer of cell therapies for heart disease.

Tencent made its fourth investment in data centre technology provider Enflame Technologies, which has now raised more than $470m altogether.

Porsche and Lockheed Martin-backed lidar sensor technology developer Aeva will get the funding once its reverse merger with InterPrivate Acquisition Corp closes.

Bristol Myers Squibb participated in a series B round for the oncology drug developer that pushed its overall funding to $168m.

The oncolytic virus therapy-based cancer drug developer raised $77m in a GV-backed series A round as it prepares to file an IND application next year.

The heart disease therapy developer completed a $12.7m round that included Alfresa, Dai-ichi Life, Sony Innovation Fund and Japan Lifeline.